Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (NCT07851207) titled 'A Study to Assess Guselkumab in Participants With Moderate-to-Severe Inflammatory Bowel Disease in Real Life Italian Setting' on Sept. 25.

Study Type: Observational

Primary Sponsor: Janssen-Cilag Ltd.

Condition: Colitis, Ulcerative Crohn Disease Inflammatory Bowel Diseases

Recruitment Status: Not recruiting

Date of First Enrollment: October 5, 2026

Target Sample Size: 200

To know more, visit https://clinicaltrials.gov/study/NCT07851207

Disclaimer: Curated by HT Syndication....